Arrowhead Pharmaceuticals Inc(ARWR)stock report

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company’s preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company’s pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.

Market Cap:5700M; Shares Outstanding:100.3M; Short Interest: 11.43%

EPS and Sales:

Date EPS % last year % last quarter
2018.12.31 -0.6186 -34.57% -14.32%
 2019.3.31 0.13 172.22% 121.02%
2019.6.30 0.39 211.43% 200.00%
 2019.9.30 0.6 213.21% 53.85%


Date Sales % last year % last quarter
2018.12.31 16.14M -48.60% 230.06%
 2019.3.31 34.66M 887.45% 114.75%
2019.6.30 82.81M 1890.56% 138.92%
 2019.9.30 126M 2467.93% 52.16%


Insider Transactions:

Institution Ownership:

Total institutions: 252,no change
Shares hold: 75561.7k shares. Reduced 1.873k
shares% hold: 79.29%,no change

Analyst Ratings:

* News:

2020.01.21: Why This Top-Notch Biotech Stock Just Plunged By Double Digits

2018.10.04: Arrowhead Enters $3.7 Billion License and Collaboration Agreements with Janssen

2016.09.29: Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations

Leave a Reply